Literature DB >> 15937084

Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment.

F Quehenberger1, H F A Vasen, H C van Houwelingen.   

Abstract

BACKGROUND: Hereditary non-polyposis colorectal cancer (HNPCC) is caused by germline mutations of mismatch repair genes, usually in hMLH1 or hMSH2. All earlier studies on penetrance except one population based study were conducted in HNPCC families and did not correct for the way in which these families were ascertained.
OBJECTIVE: To obtain estimates of the risk of colorectal cancer (CRC) and endometrial cancer (EC) for carriers of disease causing mutations of the hMSH2 and hMLH1 genes.
METHODS: Families with known germline mutations of hMLH1 (n = 39) and hMSH2 (n = 45) were extracted from the Dutch HNPCC cancer registry. Ascertainment-corrected maximum likelihood estimation was carried out on a competing risks model for cancer of the colorectum and endometrium.
RESULTS: Both loci were analysed jointly as there was no significant difference in risk (p = 0.08). At age 70, colorectal cancer risk for men was 26.7% (95% confidence interval, 12.6% to 51.0%) and for women, 22.4% (10.6% to 43.8%); the risk for endometrial cancer was 31.5% (11.1% to 70.3%).
CONCLUSIONS: Current estimates of the CRC risk of mutations to the hMLH1 and hMSH2 locus should be replaced by considerably lower risks which account for the selection of the families.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937084      PMCID: PMC1736072          DOI: 10.1136/jmg.2004.024299

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  91 in total

1.  Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma.

Authors:  Andreas Obermair; Danny R Youlden; Joanne P Young; Noralane M Lindor; John A Baron; Polly Newcomb; Susan Parry; John L Hopper; Robert Haile; Mark A Jenkins
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

2.  Understanding patterns of health communication in families at risk for hereditary nonpolyposis colorectal cancer: examining the effect of conclusive versus indeterminate genetic test results.

Authors:  Anne L Ersig; Donald W Hadley; Laura M Koehly
Journal:  Health Commun       Date:  2011-06-24

3.  Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.

Authors:  R C Niessen; M J W Berends; Y Wu; R H Sijmons; H Hollema; M J L Ligtenberg; H E K de Walle; E G E de Vries; A Karrenbeld; C H C M Buys; A G J van der Zee; R M W Hofstra; J H Kleibeuker
Journal:  Gut       Date:  2006-04-24       Impact factor: 23.059

4.  Estimating penetrance from multiple case families with predisposing mutations: extension of the 'genotype-restricted likelihood' (GRL) method.

Authors:  Bernard Bonaïti; Valérie Bonadona; Hervé Perdry; Nadine Andrieu; Catherine Bonaïti-Pellié
Journal:  Eur J Hum Genet       Date:  2010-10-06       Impact factor: 4.246

5.  Bethesda criteria for microsatellite instability testing: impact on the detection of new cases of Lynch syndrome.

Authors:  Miguel Serrano; Pedro Lage; Sara Belga; Bruno Filipe; Inês Francisco; Paula Rodrigues; Ricardo Fonseca; Paula Chaves; Isabel Claro; Cristina Albuquerque; António Dias Pereira
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

6.  Lynch syndrome: the influence of environmental factors on extracolonic cancer risk in hMLH1 c.C1528T mutation carriers and their mutation-negative sisters.

Authors:  M M Blokhuis; G E Pietersen; P A Goldberg; U Algar; L Van der Merwe; N Mbatani; A A Vorster; R S Ramesar
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

7.  Splice site mutations in mismatch repair genes and risk of cancer in the general population.

Authors:  Mette Thomsen; Børge G Nordestgaard; Anne Tybjærg-Hansen; Stig E Bojesen
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

8.  Cancer risks for MLH1 and MSH2 mutation carriers.

Authors:  James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

Review 9.  [Molecular pathogenesis. Its importance in targeted therapy in colorectal cancer].

Authors:  M Kloor; S Michel; M von Knebel Doeberitz
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

10.  Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome.

Authors:  Miriam Reuschenbach; Matthias Kloor; Monika Morak; Nicolas Wentzensen; Anja Germann; Yvette Garbe; Mirjam Tariverdian; Peter Findeisen; Michael Neumaier; Elke Holinski-Feder; Magnus von Knebel Doeberitz
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.